Hey all - long time reader of all things PTX here. I've got a question regarding the response rates/benefit rates presented at the latest briefing - hoping someone could shed some light on.
The stats around the Overall Response Rates & Clinical Benefit Rates are composed of patients that have reached the end of cycle 4 of treatment (a cycle being 14 days). Most of the more recent patients unfortunately haven't reaching this time point. My question is around why the ORR/CBR is measured with the cohort of patients that have reached the end of C4? I'm assuming this has to do with the study design - but clarification would be helpful! Is this benchmark typical for a study like ours?
From the swimmer plot, a number of patients would have gone through about 2 cycles of treatment. If the benchmark is arbitrary, and hypothetically we were to include these patients in calculating efficacy - does this mean PTX100 may not be as effective?
PTX Price at posting:
6.4¢ Sentiment: Buy Disclosure: Held
